Sponsored Links 
BioMarin a Buy with a $28 Target
BioMarin Pharmaceutical Inc. (BMRN - Analyst Report) develops enzyme therapies for serious chronic genetic disorders and other diseases. Its leading product, Aldurazyme, is used for treating the ultra-rare genetic disorder
mucopolysaccharidosis-I (MPS-I) while its second product, Naglazyme, is appoved for the treatment of MPS-VI.
Recently, the company received both FDA and EC approval for its third product, Kuvan, for the treatment of PKU. Strong product sales will drive the company to profitability in 2008 and beyond.
The company's clinical pipeline, too, remains impressive. As such, we maintain our Buy rating on the stock with a price target of $28.
Read the full analyst report on BMRN
 |
 |
 Share |
 RSS |
 Rate Pos |
 Rate Neg |
 Comment |
|
|
||||||
Loading Stories...Related Content
Loading Stories...Most Popular on Zacks.com
1.23 %
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Nov 08, 2009 12:41 pm ET |
Sponsored Links
[CLICK TO CLOSE X]